Non-response to Communication Technology Outreach for Beta-agonist Overuse in a Pragmatic Randomized Trial of Patients with Asthma.
Non-response to Communication Technology Outreach for Beta-agonist Overuse in a Pragmatic Randomized Trial of Patients with Asthma.
复制标题
在哮喘患者的务实随机试验中，对过度使用β受体激动剂的通信技术外展没有反应。
DOI：
10.1007/s11606-018-4395-9
复制
发表时间：
2018
影响因子：
5.7
通讯作者：
Bender,BruceG
中科院分区：
文献类型：
--
作者：
Raebel,MarshaA;Shetterly,SusanM;Goodrich,GlennK;Anderson,CourtneyB;Shoup,JoAnn;Wagner,Nicole;Bender,BruceG
METHODSThis work was conducted at Kaiser Permanente Colorado (KPCO), an integrated healthcare system with approximately 600,000 members in the Denver-Boulder area. In KPCO usual care, when a patient refills a beta-agonist more frequently than every 60 days, an asthma care coordinator (ACC) is notified through the electronic health record (EHR) for patient follow-up. Because there are many reasons a patient could overfill (eg, extra inhaler for gym), knowledge of current asthma symptoms is important, but unavailable to the ACC until after s/he contacts the patient. The electronic outreach was designed to determine whether the patient currently had symptoms to guide further contact.
